about
MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemiaRetrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project DatabaPeripheral T-cell lymphoma, unspecified--the analysis of the data from the Czech Lymphoma Study Group (CLSG) registry.The results of allogeneic transplants in patients with malignant lymphoma-a retrospective analysis of data from the Czech National Registry.Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absentEstimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy.Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup studyIntrapleural bortezomib for the therapy of myelomatous pleural effusion: a case report.CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.Microscopic notes on the perinucleolar chromatin region in immature and mature human B-leukemia lymphocytes.Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab eraTreatment of older patients with mantle-cell lymphoma.Expression patterns of microRNAs associated with CML phases and their disease related targets.Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin LymphomaRituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphomaA randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma.Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care.Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference.ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trialLong-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research.Multi-level disruption of the extrinsic apoptotic pathway mediates resistance of leukemia cells to TNF-related apoptosis-inducing ligand (TRAIL).Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database.5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis.The quality of life following allogeneic hematopoietic stem cell transplantation - a multicenter retrospective study.
P50
Q28304835-E67C286F-0FEA-48C2-B2EC-2A5947F911A6Q30649483-4B0B0EEA-6D7C-4D22-A2D3-764624CA9F6AQ31121474-BBB4CD08-A9A8-4B77-96F6-31CB6405DECDQ33400797-E8CE8511-72DF-4C77-BF82-BBE7FB271811Q33419843-44E37260-4A29-4ED8-B540-28968F69DCBFQ33430165-150653CE-A298-4A36-B528-B06B9D4FD67CQ33433426-D45FDB1B-67A1-4968-9E47-0820DFCDC7CFQ33440715-A2B174D5-ED11-4A9F-A8EB-EA6D6E5295E5Q33822710-61E00910-7142-4D31-94DA-CE21222F3062Q33890300-64496A76-3DAE-4BF1-BEB0-323B82A06AAAQ33945770-2C1CDC1C-B178-4187-9400-2B7CB350BDD7Q34046343-143D73CA-DEAA-4A86-8177-FAD5BABC1358Q34095473-28DC757A-C942-456E-8C17-B10AFBD6AADDQ34394503-DDDE4933-5504-4C52-84D6-2BF76992BE79Q34566901-96DEBB39-7677-4B37-B5CB-B8D194071A18Q34571955-A593B880-20A9-4331-B804-9DA0DBE969BEQ34617307-A5DBB8AC-BDA9-4E13-BBA0-49ED61F2B232Q34621900-FEE14E0B-2178-439E-96A5-311F7F28CF3AQ34641279-5A1CB7BD-0004-47F3-86ED-3B82C510FF92Q35009176-CF353110-48D5-4E38-832D-A98DA34FEC86Q35800846-9CE179F7-5D14-4931-9995-A44C615B293CQ35823280-60724200-E849-4B2D-83D7-0E9940B094A8Q36822155-203EBE4B-4F86-458A-9B55-E71E96ECBA5DQ37301456-083F1A49-FDD2-4C97-86F7-BBF3CBA1763EQ37547188-0F1CEAC8-CA82-460E-8235-C0DBCB5A7076Q37772500-C255B892-A15C-4086-BA7A-DD88F0ACCF1EQ38061883-8463C270-54E7-40B7-ABFA-AB092D65F04CQ38644362-54A1D58D-D386-40B8-B930-24AE91576979Q38670952-A838ECBC-D05C-448F-9166-026491EC91EEQ38716342-DBCB60EF-79B4-42EE-8C3A-15E57686ED3BQ38827910-C6A389FC-2C03-44E4-BE43-85895156223BQ38906747-F64B0349-2E47-42E3-B6D4-8229F379290DQ38939585-BE8CA6AF-6846-42F9-908D-A4FD8EAC08C3Q38991388-33008602-2E3E-459B-82E2-E37046247617Q39222481-B9E5E2FB-5E9D-4EB0-8B72-DE4F0245AA61Q39308464-C128B28D-E23A-455A-A367-C5C4EBDD91A2Q39353147-3A12812D-773C-4AB2-9D8E-7BAE60A9E85FQ39395000-891F4658-E185-4FE4-B954-C09C09433BE0Q39505206-C8DB74B8-CC4E-4C60-95B0-6964BD5BC55EQ39549578-C78F3FA2-78A5-415B-ACBA-87B32A4F7433
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Marek Trneny
@ast
Marek Trneny
@es
Marek Trneny
@nl
Marek Trneny
@sl
Marek Trněný
@cs
Marek Trněný
@en
type
label
Marek Trneny
@ast
Marek Trneny
@es
Marek Trneny
@nl
Marek Trneny
@sl
Marek Trněný
@cs
Marek Trněný
@en
altLabel
M.Trneny
@en
M.Trněný
@en
Marek Trneny
@en
Marek Trněný
@en
Trneny M
@en
Trněný M.
@en
prefLabel
Marek Trneny
@ast
Marek Trneny
@es
Marek Trneny
@nl
Marek Trneny
@sl
Marek Trněný
@cs
Marek Trněný
@en
P214
P106
P1153
6701742782
P21
P214
P31
P496
0000-0002-6952-6073
P569
1960-01-01T00:00:00Z
P691
nlk20000083659
P735
P7859
viaf-84793973